Nanobiotix ( (NBTX) ) just unveiled an update.
On March 20, 2025, Nanobiotix announced the presentation of data from two Phase 1 studies evaluating their product JNJ-1900 (NBTXR3) at the European Lung Cancer Conference. This product, a novel oncology treatment using hafnium oxide nanoparticles, is activated by radiotherapy and is being tested for safety and efficacy in treating lung cancer. The studies aim to expand the potential applications of NBTXR3 in combination with immune checkpoint inhibitors, which could significantly impact the company’s market positioning and offer new treatment possibilities for patients with solid tumors.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company, founded in 2003 and headquartered in Paris, France. The company is known for pioneering nanoparticle-based therapeutic approaches aimed at improving treatment outcomes for cancer and other major diseases. It is publicly traded on Euronext Paris and the Nasdaq Global Select Market. Nanobiotix owns over 25 patents related to nanotechnology platforms with applications in oncology, bioavailability, biodistribution, and central nervous system disorders.
YTD Price Performance: 31.03%
Average Trading Volume: 16,987
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $178.2M
See more data about NBTX stock on TipRanks’ Stock Analysis page.